Faculty Appointments
Patient Care Setting
Cancer
Biography
There are general principles of cancer care that have withstood the test of time. However, scientific and technologic advances are being made rapidly. As an oncologist, I always remember that a patient is at the end of every stethoscope, robot, sequencing machine and so on.
I chose this field because it is most interdisciplinary and dynamic – plus, I work with a team of outstanding colleagues. I have a special interest in what was once called tumor immunology, now referred to as immuno-oncology.
Conditions I Treat
- Melanoma
- Prostate cancer
- Urinary cancer
- Bladder cancer
- Kidney cancer
- Testicular cancer
- Penile cancer
- Sarcomas
- Rare cancers such as Merkel cell carcinoma and Kaposi's sarcoma
Professional Background
Deepak Sahasrabudhe is a Professor of Medicine in the Division of Hematology/Oncology at the James P. Wilmot Cancer Center at the University of Rochester School of Medicine and Dentistry in Rochester, New York. Dr. Sahasrabudhe received his training at Albany Medical Center Hospital in Albany, New York and the University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Dr. Sahasrabudhe is a key teaching faculty member in the Hematology/Oncology Fellowship Program. He has mentored several fellows over the last 17 years.
Dr. Sahasrabudhe's clinical research interest is in urologic malignancies. He also sees patients with melanomas and sarcomas.
Dr. Sahasrabudhe is a member of many national professional organizations including the American College of Physicians, the American Association for Cancer Research, and the American Society of Clinical Oncology.
Credentials
Education
1974
MD | University of Bombay
Post-doctoral Training & Residency
07/01/1982 - 06/01/1986
Fellowship in Cancer Research at University of Rochester Medical Center
07/01/1979 - 06/30/1982
Fellowship in Hematology/Oncology at University of North Carolina School of Medicine
07/01/1977 - 06/30/1979
Residency in Internal Medicine at Albany Medical Center
07/01/1976 - 06/30/1977
Internship in Internal Medicine at Albany Medical Center
VIEW ALL expand_more
Awards
2009
Gitelman Award
Sponsor: Gilda's Club
Location: Rochester, NY
Clinical Trials
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies (MK6482-005)
Lead Researcher: Deepak Madhao Sahasrabudhe MD
The primary objective of this study is to compare MK-6482 to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that MK-6482 is superior to everolimus with respect to PFS and OS.
View Study Details
A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301),
Lead Researcher: Deepak Madhao Sahasrabudhe MD
A Phase 3 global, multi-center, open-label comparison of ipilimumab with and without intratumoral IMO-2125 in subjects with advanced melanoma who had confirmed disease progression while on nivolumab or pembrolizumab
View Study Details
Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716),Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716),Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)
Lead Researcher: Deepak Madhao Sahasrabudhe MD
Pembrolizumab is an antibody that blocks a protective mechanism of cancer cells and thereby allows the immune system to destroy them. This study will evaluate pembrolizumab compared to placebo in participants after the surgical removal of stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design for up to 17 cycles. Part 2 is an open-label design for participants who receive placebo in Part 1 or who stop treatment after receiving 17 cycles of pembrolizumab in Part 1. They may be eligible to receive up to 35 additional cycles of pembrolizumab in Part 2.
View Study Details
UGUP17050: A pilot study of cisplatin in castration resistant prostate cancer that is becoming refractory to enzalutamide
Lead Researcher: Deepak Madhao Sahasrabudhe MD
If you choose to participate in this study, you will receive cisplatin once per week for 6 weeks and you will continue to receive leuprolide and enzalutamide. You will also have blood samples collected at enrollment, 3 weeks, 5 weeks, and conclusion of treatment for research purposes.
View Study Details
BMS: Pilot study of Neoadjuvant Dual checkpoint blockade with concurrent radiation in resectable soft tissue sarcoma
Lead Researcher: Deepak Madhao Sahasrabudhe MD
The main aim of immunotherapy is to enable patients' immune system to target cancer cells and destroy them. This study will treat patients with soft tissue sarcoma (cancer) with neoadjuvant nivolumab and ipilimumab, antibodies that can be used as immunotherapies. Patients will also receive concurrent radiation therapy. Following these treatments will be the surgical removal of the patent's soft tissue sarcoma.
View Study Details
Pilot Study of Neoadjuvant Dual Checkpoint Blockade With Concurrent Radiation in Resectable Soft Tissue Sarcoma
Lead Researcher: Deepak Madhao Sahasrabudhe MD
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
View Study Details
CMEL-15088 EA6134: “A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma”
Lead Researcher: Deepak Madhao Sahasrabudhe MD
The BRAF inhibitor component will include two drugs dabrafenib and trametinib that each have been approved by the FDA for the treatment of this patient population and have also been approved for use in combination due to superior effects relative to the single agent treatments. In addition, the study will involve the addition of the FDA approved agent nivolumab to the standard FDA approved ipilimumab immunotherapy in the hopes that it might further improve the good effects of the immunotherapy component of the treatment sequence.
View Study Details
UGUP-14091: Isolation and manipulation of circulating tumor cells in prostate cancer: A feasibility study
Lead Researcher: Deepak Madhao Sahasrabudhe MD
If you decide to participate in this study, your blood will be drawn periodically before, during and after therapy. You will be asked to provide ¬¬¬¬1.5 teaspoons of blood at a time. Blood samples will be collected before start of treatment and then approximately every one to three weeks for up to 12 months.
View Study Details
Publications
Journal Articles
6/2018
Dineen M, Hansen E, Guancial E, Sievert L, Sahasrabudhe D. "Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature." Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.. 2018 Jun 0; 24(4):314-318. Epub 2017 Mar 29.
5/20/2018
Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, Stump TE, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard C, Huddart RA, Kim J, Kollmannsberger C, Sahasrabudhe DM, Cook R, Fossa SD, Einhorn LH, Travis LB, . "Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2018 May 20; 36(15):1505-1512. Epub 2018 Apr 04.
11/2016
Pan C, Singh S, Sahasrabudhe DM, Chakkalakal JV, Krolewski JJ, Nastiuk KL. "TGF? Superfamily Members Mediate Androgen Deprivation Therapy-Induced Obese Frailty in Male Mice." Endocrinology.. 2016 Nov 0; 157(11):4461-4472. Epub 2016 Sep 09.
Books & Chapters
2001
Chapter Title: Soft Tissue Sarcoma
Book Title: Clinical Oncology, 8th Edition
Author List: Spiro, IJ; Suit, HD; Rosier, RN; Sahasrabudhe, DM
Edited By: Rubin P.
Published By: W.B. Saunders Company, Harcourt Brace Jovanovich Inc 2001 in Philadelphia PA
2001
Chapter Title: Bone Tumors
Book Title: Clinical Oncology, 8th Edition
Author List: Rosier, RN; O'Keefe, RJ; Sahasrabudhe, DM
Edited By: Rubin P.
Published By: W.B. Saunders Company, Harcourt Brace Jovanovich, Inc 2001 in Philadelphia PA
VIEW ALL PUBLICATIONS